Chronic Heart Failure Market and Forecast Analysis to 2024

  • ID: 4462134
  • Report
  • 356 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Chronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, but structural disorders of the heart muscle or valves are also common causes. While current therapies have helped to improve patient outcomes, CHF still remains a major public health issue and is associated with high mortality rates and a poor prognosis.

Market Snapshot
  • Entresto will be the main driver of growth within the chronic heart failure market during the forecast period.
  • Novel CHF treatments have yet to alter prescribing practices from traditional ACE inhibitors and beta blockers.
  • CHF prevalence rises with age, with 55-84 years comprising three-quarters of all diagnosed prevalent cases in adults.
  • Entresto has overcome initial barriers to uptake and has the potential to change CHF treatment practices.
  • Despite a full pipeline it is unlikely that any candidates have the potential to significantly change treatment practices.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: CHRONIC HEART FAILURE (Published on 11 December 2017)
EXECUTIVE SUMMARY
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE (LATE STAGE): C-CURE
PRODUCT PROFILE: CORLANOR
PRODUCT PROFILE: ENTRESTO
PRODUCT PROFILE (LATE STAGE): FARXIGA
PRODUCT PROFILE (LATE STAGE): JARDIANCE
PRODUCT PROFILE (LATE STAGE): MPC-150-IM
PRODUCT PROFILE (LATE STAGE): XARELTO
PRODUCT PROFILE (LATE STAGE): OMECAMTIV MECARBIL
PRODUCT PROFILE (LATE STAGE): VERICIGUAT

TREATMENT: CHRONIC HEART FAILURE (Published on 04 October 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS: CHF WITH REDUCED EJECTION FRACTION
PRESCRIBING TRENDS: CHF WITH PRESERVED EJECTION FRACTION
COMPLIANCE RATES

EPIDEMIOLOGY: CHRONIC HEART FAILURE (Published on 09 October 2017)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
METHODOLOGY
FORECAST
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: CHRONIC HEART FAILURE (Published on 11 December 2017)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
ANGIOTENSIN RECEPTOR BLOCKERS
BETA BLOCKERS
ALDOSTERONE ANTAGONISTS
OTHER DRUG CLASSES
PRODUCT PROFILE: CORLANOR
PRODUCT PROFILE: ENTRESTO

PIPELINE: CHRONIC HEART FAILURE (Published on 11 December 2017)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): C-CURE
PRODUCT PROFILE (LATE STAGE): FARXIGA
PRODUCT PROFILE (LATE STAGE): JARDIANCE
PRODUCT PROFILE (LATE STAGE): MPC-150-IM
PRODUCT PROFILE (LATE STAGE): XARELTO
PRODUCT PROFILE (LATE STAGE): OMECAMTIV MECARBIL
PRODUCT PROFILE (LATE STAGE): VERICIGUAT

List of Figures
Figure 1: Chronic heart failure - current and future market dynamics analysis
Figure 2: The author’s assessment summary of key marketed and pipeline drugs for chronic heart failure
Figure 3: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Sales of Jardiance and Farxiga in the US, Japan, and five major EU markets, 2017-26
Figure 6: Sales of generic ACE inhibitors and ARBs in the US, Japan, and five major EU markets, 2017-26
Figure 7: Sales of MPC-150-IM and C-Cure in the US, Japan, and five major EU markets, 2017-26
Figure 8: Sales of vericiguat and omecamtiv mecarbil in the US, Japan, and five major EU markets, 2017-26
Figure 9: Sales of Xarelto and rivaroxaban generics in the US, Japan, and five major EU markets, 2017-26
Figure 10: Chronic heart failure drug sales in the US, by class, 2017-26
Figure 11: Chronic heart failure drug sales in the five major EU markets, by country, 2017-26
Figure 12: Chronic heart failure drug sales in the five major EU markets, by class, 2017-26
Figure 13: Chronic heart failure drug sales in Japan, by class, 2017-26
Figure 14: Methodology flow for the author's chronic heart failure forecast
Figure 15: Price sources and calculations, by country
Figure 16: C-Cure for chronic heart failure - SWOT analysis
Figure 17: Drug assessment summary of C-Cure for chronic heart failure
Figure 18: Drug assessment summary of C-Cure for chronic heart failure
Figure 19: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 20: Corlanor for chronic heart failure - SWOT analysis
Figure 21: Drug assessment summary of Corlanor for chronic heart failure
Figure 22: Drug assessment summary of Corlanor for chronic heart failure
Figure 23: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 24: Entresto for chronic heart failure - SWOT analysis
Figure 25: Drug assessment summary of Entresto for chronic heart failure
Figure 26: Drug assessment summary of Entresto for chronic heart failure
Figure 27: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 28: Farxiga for chronic heart failure - SWOT analysis
Figure 29: Drug assessment summary of Farxiga for chronic heart failure
Figure 30: Drug assessment summary of Farxiga for chronic heart failure
Figure 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 32: Jardiance for chronic heart failure - SWOT analysis
Figure 33: Drug assessment summary of Jardiance for chronic heart failure
Figure 34: Drug assessment summary of Jardiance for chronic heart failure
Figure 35: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 36: MPC-150-IM for chronic heart failure - SWOT analysis
Figure 37: Drug assessment summary of MPC-150-IM for chronic heart failure
Figure 38: Drug assessment summary of MPC-150-IM for chronic heart failure
Figure 39: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 40: Xarelto for chronic heart failure - SWOT analysis
Figure 41: Drug assessment summary of Xarelto for chronic heart failure
Figure 42: Drug assessment summary of Xarelto for chronic heart failure
Figure 43: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 44: Omecamtiv mecarbil for chronic heart failure - SWOT analysis
Figure 45: Drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 46: Drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 47: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 48: Vericiguat for chronic heart failure - SWOT analysis
Figure 49: Drug assessment summary of vericiguat for chronic heart failure
Figure 50: Drug assessment summary of vericiguat for chronic heart failure
Figure 51: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 52: Diagnostic flow chart for patients with suspected heart failure
Figure 53: Percentage incidence of co-morbidities among chronic heart failure patients in the US, Japan, and five major EU markets, by co-morbidity/risk factor
Figure 54: Percentage of CHF patients across the US, Japan, and five major EU markets who are over the age of 65, diagnosed with hypertension, or diagnosed with CAD
Figure 55: Percentage of CHF patients diagnosed with HFrEF and HFpEF across the US, Japan, and five major EU markets, by country
Figure 56: Percentage of patients with HFrEF in each NYHA class, by country
Figure 57: Percentage of patients with HFpEF in each NYHA class, by country
Figure 58: Percentage of HFrEF patients receiving each treatment type, by NYHA class
Figure 59: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFrEF, by NYHA class and country
Figure 60: Percentage of regimens containing beta blockers for the first-line treatment of HFrEF, by NYHA class and country
Figure 61: Percentage of regimens containing ARBs for the first-line treatment of HFrEF, by NYHA class and country
Figure 62: Percentage of regimens containing ARBs for the treatment of HFrEF, by NYHA class and line of treatment
Figure 63: Percentage of regimens containing diuretics for the first-line treatment of HFrEF, by country and NYHA class
Figure 64: Percentage of regimens containing MRAs for the first-line treatment of HFrEF, by country and NYHA class
Figure 65: Percentage of regimens containing SGLT-2 inhibitors for the first-line treatment of HFrEF, by country and NYHA class
Figure 66: Percentage of regimens containing the SGLT-2 inhibitors Jardiance and Farxiga for the first-line treatment of HFrEF, by NYHA class
Figure 67: Top three drug regimens for first-line treatment of class I HFrEF, by country
Figure 68: Top three drug regimens for second-line treatment of class I HFrEF, by country
Figure 69: Top three drug regimens for first-line treatment of class II-III HFrEF, by country
Figure 70: Top three drug regimens for second-line treatment of class II-III HFrEF, by country
Figure 71: Top three drug regimens for first-line treatment of class IV HFrEF, by country
Figure 72: Top three drug regimens for second-line treatment of class IV HFrEF, by country
Figure 73: Percentage of HFpEF patients receiving each treatment type, by NYHA class
Figure 74: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFpEF, by NYHA class and country
Figure 75: Percentage of regimens containing ARBs for the first-line treatment of HFpEF, by NYHA class and country
Figure 76: Percentage of regimens containing beta blockers for the first-line treatment of HFpEF, by country and NYHA class
Figure 77: Percentage of regimens containing diuretics for the first-line treatment of HFpEF, by country and NYHA class
Figure 78: Percentage of regimens containing MRAs for the first-line treatment of HFpEF, by country and NYHA class
Figure 79: Top three drug regimens for first-line treatment of class I HFpEF, by country
Figure 80: Top three drug regimens for second-line treatment of class I HFpEF, by country
Figure 81: Top three drug regimens for first-line treatment of class II-III HFpEF, by country
Figure 82: Top three drug regimens for second-line treatment of class II-III HFpEF, by country
Figure 83: Top three drug regimens for first-line treatment of class IV HFpEF, by country
Figure 84: Top three drug regimens for second-line treatment of class IV HFpEF, by country
Figure 85: Compliance rates of chronic heart failure patients in the US, Japan, and five major EU markets, by country and ejection fraction
Figure 86: Trends in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016-36
Figure 87: Absolute change in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016-36
Figure 88: Corlanor for chronic heart failure - SWOT analysis
Figure 89: Drug assessment summary of Corlanor for chronic heart failure
Figure 90: Drug assessment summary of Corlanor for chronic heart failure
Figure 91: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 92: Entresto for chronic heart failure - SWOT analysis
Figure 93: Drug assessment summary of Entresto for chronic heart failure
Figure 94: Drug assessment summary of Entresto for chronic heart failure
Figure 95: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 96: C-Cure for chronic heart failure - SWOT analysis
Figure 97: Drug assessment summary of C-Cure for chronic heart failure
Figure 98: Drug assessment summary of C-Cure for chronic heart failure
Figure 99: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 100: Farxiga for chronic heart failure - SWOT analysis
Figure 101: Drug assessment summary of Farxiga for chronic heart failure
Figure 102: Drug assessment summary of Farxiga for chronic heart failure
Figure 103: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 104: Jardiance for chronic heart failure - SWOT analysis
Figure 105: Drug assessment summary of Jardiance for chronic heart failure
Figure 106: Drug assessment summary of Jardiance for chronic heart failure
Figure 107: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 108: MPC-150-IM for chronic heart failure - SWOT analysis
Figure 109: Drug assessment summary of MPC-150-IM for chronic heart failure
Figure 110: Drug assessment summary of MPC-150-IM for chronic heart failure
Figure 111: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 112: Xarelto for chronic heart failure - SWOT analysis
Figure 113: Drug assessment summary of Xarelto for chronic heart failure
Figure 114: Drug assessment summary of Xarelto for chronic heart failure
Figure 115: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 116: Omecamtiv mecarbil for chronic heart failure - SWOT analysis
Figure 117: Drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 118: Drug assessment summary of omecamtiv mecarbil for chronic heart failure
Figure 119: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 120: Vericiguat for chronic heart failure - SWOT analysis
Figure 121: Drug assessment summary of vericiguat for chronic heart failure
Figure 122: Drug assessment summary of vericiguat for chronic heart failure
Figure 123: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 2: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 3: SGLT-2 inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 4: Generic ACE inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Generic ARB sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Generic ACE inhibitor patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Table 7: Generic ARB patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Table 8: Stem cell therapy sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 9: Stem cell therapy patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Table 10: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 11: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 13: Chronic heart failure drug sales across the US and five major EU markets, by country ($m), 2017-26
Table 14: Summary of drug classes and molecules included in the author’s chronic heart failure patient-based forecast
Table 15: Exchange rates used for calculating prices
Table 16: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 17: C-Cure drug profile
Table 18: C-Cure’s proposed Phase III trial design in chronic heart failure
Table 19: C-Cure completed late-phase data in chronic heart failure
Table 20: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 21: Corlanor drug profile
Table 22: Corlanor pivotal phase III trial data in chronic heart failure
Table 23: Corlanor Phase II trial data in chronic heart failure
Table 24: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 25: Entresto drug profile
Table 26: Entresto Phase III data in chronic heart failure
Table 27: Ongoing pivotal trials for Entresto in chronic heart failure
Table 28: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 29: Farxiga drug profile
Table 30: Farxiga Phase III trials in chronic heart failure
Table 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 32: Jardiance drug profile
Table 33: Jardiance Phase III trials in chronic heart failure
Table 34: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 35: MPC-150-IM drug profile
Table 36: MPC-150-IM’s late-phase trials in chronic heart failure
Table 37: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 38: Xarelto drug profile
Table 39: Xarelto Phase III data in chronic heart failure
Table 40: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 41: Omecamtiv mecarbil drug profile
Table 42: Omecamtiv mecarbil Phase III study in chronic heart failure
Table 43: Omecamtiv mecarbil Phase II data in chronic heart failure
Table 44: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 45: Vericiguat drug profile
Table 46: Vericiguat Phase III trials in chronic heart failure
Table 47: Vericiguat Phase II data in chronic heart failure
Table 48: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 49: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 50: Common laboratory test abnormalities in chronic heart failure
Table 51: Definitions of HFrEF and HFpEF
Table 52: New York Heart Association functional classification based on severity of symptoms and physical activity
Table 53: Comparison of ACCF/AHA stages of HF with NYHA functional classification
Table 54: Treatments available for chronic heart failure across the US, Japan, and five major EU markets
Table 55: NYHA functional classes I-IV, classification summary
Table 56: Sources used for the epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country
Table 57: Diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016-36
Table 58: Age-specific diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016
Table 59: Gender-specific diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016
Table 60: Subtype-specific diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2016
Table 61: Reduced EF diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country and NYHA class, 2016
Table 62: Preserved EF diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country and NYHA class, 2016
Table 63: Key marketed drugs for chronic heart failure
Table 64: Angiotensin-converting enzyme inhibitors class overview
Table 65: Angiotensin receptor blocker class overview
Table 66: Beta blocker class overview
Table 67: Aldosterone antagonists class overview
Table 68: Other drug class overview
Table 69: Corlanor drug profile
Table 70: Corlanor pivotal phase III trial data in chronic heart failure
Table 71: Corlanor Phase II trial data in chronic heart failure
Table 72: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 73: Entresto drug profile
Table 74: Entresto Phase III data in chronic heart failure
Table 75: Ongoing pivotal trials for Entresto in chronic heart failure
Table 76: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 77: Profiled pipeline products in development for chronic heart failure
Table 78: C-Cure drug profile
Table 79: C-Cure’s proposed Phase III trial design in chronic heart failure
Table 80: C-Cure completed late-phase data in chronic heart failure
Table 81: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 82: Farxiga drug profile
Table 83: Farxiga Phase III trials in chronic heart failure
Table 84: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 85: Jardiance drug profile
Table 86: Jardiance Phase III trials in chronic heart failure
Table 87: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 88: MPC-150-IM drug profile
Table 89: MPC-150-IM’s late-phase trials in chronic heart failure
Table 90: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 91: Xarelto drug profile
Table 92: Xarelto Phase III data in chronic heart failure
Table 93: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 94: Omecamtiv mecarbil drug profile
Table 95: Omecamtiv mecarbil Phase III study in chronic heart failure
Table 96: Omecamtiv mecarbil Phase II data in chronic heart failure
Table 97: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 98: Vericiguat drug profile
Table 99: Vericiguat Phase III trials in chronic heart failure
Table 100: Vericiguat Phase II data in chronic heart failure
Table 101: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll